CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 131 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.09 and the average weighting 0.0%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $32,978 | -38.7% | 25,565 | -18.2% | 0.00% | – |
Q2 2023 | $53,770 | -11.0% | 31,262 | -21.9% | 0.00% | – |
Q1 2023 | $60,447 | -10.1% | 40,031 | -4.7% | 0.00% | – |
Q4 2022 | $67,214 | +253.8% | 42,009 | +221.0% | 0.00% | – |
Q3 2022 | $19,000 | -44.1% | 13,088 | -28.3% | 0.00% | – |
Q2 2022 | $34,000 | -12.8% | 18,253 | +24.1% | 0.00% | – |
Q1 2022 | $39,000 | -82.4% | 14,705 | -71.2% | 0.00% | – |
Q4 2021 | $221,000 | +37.3% | 51,107 | +61.5% | 0.00% | – |
Q3 2021 | $161,000 | +1.9% | 31,651 | +26.8% | 0.00% | – |
Q2 2021 | $158,000 | -56.6% | 24,959 | -47.1% | 0.00% | – |
Q1 2021 | $364,000 | +160.0% | 47,204 | +121.8% | 0.00% | – |
Q4 2020 | $140,000 | -64.3% | 21,279 | -63.9% | 0.00% | – |
Q3 2020 | $392,000 | +51.4% | 59,022 | +89.9% | 0.00% | – |
Q2 2020 | $259,000 | +43.1% | 31,081 | +32.0% | 0.00% | – |
Q1 2020 | $181,000 | -23.6% | 23,549 | -17.7% | 0.00% | – |
Q4 2019 | $237,000 | -47.9% | 28,626 | -53.6% | 0.00% | – |
Q3 2019 | $455,000 | -59.6% | 61,693 | -38.6% | 0.00% | – |
Q2 2019 | $1,127,000 | -17.7% | 100,512 | -21.1% | 0.00% | – |
Q1 2019 | $1,370,000 | +63.3% | 127,443 | +129.3% | 0.00% | – |
Q4 2018 | $839,000 | -13.1% | 55,574 | +6.5% | 0.00% | – |
Q3 2018 | $965,000 | -67.2% | 52,158 | -59.4% | 0.00% | – |
Q2 2018 | $2,939,000 | -48.3% | 128,587 | -35.6% | 0.00% | -100.0% |
Q1 2018 | $5,680,000 | +121.9% | 199,664 | +64.6% | 0.00% | – |
Q4 2017 | $2,560,000 | +46.4% | 121,273 | +26.0% | 0.00% | – |
Q3 2017 | $1,749,000 | +7.6% | 96,232 | -8.2% | 0.00% | – |
Q2 2017 | $1,625,000 | +20.3% | 104,811 | +34.0% | 0.00% | – |
Q1 2017 | $1,351,000 | +4.2% | 78,223 | -33.7% | 0.00% | – |
Q4 2016 | $1,297,000 | +16.0% | 117,990 | +65.4% | 0.00% | – |
Q3 2016 | $1,118,000 | +3287.9% | 71,324 | +2157.8% | 0.00% | – |
Q2 2016 | $33,000 | +43.5% | 3,159 | +80.1% | 0.00% | – |
Q1 2016 | $23,000 | -45.2% | 1,754 | -12.6% | 0.00% | – |
Q4 2015 | $42,000 | – | 2,006 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |